CMLD-2

CMLD-2 is a small molecule inhibitor of the RNA-binding protein Human antigen R (HuR), also known as ELAVL1. HuR is a post-transcriptional regulator that binds to adenylate-uridylate-rich elements (AREs) in the 3' untranslated regions of various mRNAs, stabilizing them and promoting the translation of proteins involved in cell proliferation, survival, and stress response. CMLD-2 competitively binds to the RNA-binding domain of HuR (specifically the RRM1 and RRM2 motifs), preventing its interaction with target mRNAs such as E2F7, cyclin D1, and VEGF. This disruption leads to the degradation of these oncogenic transcripts and subsequent inhibition of tumor growth. Preclinical research has demonstrated that CMLD-2 has significant anti-tumor activity in multiple myeloma, lung cancer, and colon cancer models, and it has shown synergistic effects when combined with proteasome inhibitors like bortezomib.

Other names

HuR inhibitor CMLD-24-methyl-2-oxo-2H-chromen-7-yl 4-chlorobenzoate